Search results for "Combination"

showing 10 items of 1379 documents

Structural and electronic properties of β-NaYF4 and β-NaYF4:Ce3+

2020

AP is indebted for a financial support provided by Scientific Research Project grant for Students and Young Researchers Nr. SJZ/2017/3 sponsored at the Institute of Solid State Physics, University of Latvia , while AIP is thankful for the financial support from Latvian Research Council lzp-2018/1-0214 .

Band gapAb initio02 engineering and technologyCrystal structure010402 general chemistry01 natural sciencesMolecular physicsIonInorganic ChemistryLattice constantDoping:NATURAL SCIENCES:Physics [Research Subject Categories]Electrical and Electronic EngineeringPhysical and Theoretical ChemistrySpectroscopyPhysicsab initioOrganic ChemistrySpace group021001 nanoscience & nanotechnologyRare earth luminescencerAtomic and Molecular Physics and Optics0104 chemical sciencesElectronic Optical and Magnetic MaterialsLinear combination of atomic orbitalsDensity functional theoryDefects0210 nano-technologyOptical Materials
researchProduct

Comparative analysis of the electronic structures of mono- and bi-atomic chains of IV, III–V and II–VI group elements calculated using the DFT LCAO a…

2015

Using the first principle non-relativistic linear combination of atomic orbitals (LCAO) and relativistic linearized augmented cylindrical wave (LACW) methods, the band structure of the covalent and partially ionic ANB8−N single atom width chain is calculated. Both the LCAO and LACW methods show that the chains of C, Si, Ge, Sn, and Pb are metallic. However, there is a great difference between the relativistic and non-relativistic band structures. The π bands crossing the Fermi level are orbitally doubly degenerate in the non-relativistic model. The relativistic LACW calculations demonstrate that the spin and orbital motion of electrons are coupled, thereby splitting the π bands. The spin–or…

Band gapChemistryGeneral Chemical EngineeringFermi levelIonic bondingGeneral ChemistryElectronic structuresymbols.namesakeLinear combination of atomic orbitalsAtomsymbolsDensity of statesAtomic physicsElectronic band structureRSC Advances
researchProduct

Influence of a bioceramic root end material and mineral trioxide aggregates on fibroblasts and osteoblasts

2012

The biocompatibility of materials used in endodontic treatment is of high importance, because they can come in contact with periradicular tissues and there is a risk of possible systemic toxicity. The aim of the present study was to investigate the in vitro reaction to a bioceramic based root end material in comparison to mineral trioxide aggregates (MTA) as the established gold standard.The root end materials grey MTA Angelus (GMTA), white MTA Angelus (WMTA), ProRoot MTA, and EndoSequence Root Repair Material (ERRM) were incubated with human periodontal ligament fibroblasts and osteoblasts (10(4)cells/ml) for up to 96h. Cell proliferation (RFU) was determined by means of the Alamar Blue as…

BiocompatibilityPeriodontal LigamentCell Culture TechniquesDentistryBiocompatible MaterialsBioceramicRoot Canal Filling Materialschemistry.chemical_compoundHumansAluminum CompoundsGeneral DentistryCell ProliferationOsteoblastsbusiness.industrySilicatesOxidesCell BiologyGeneral MedicineCalcium CompoundsFibroblastsDrug CombinationsPeriradicularSystemic toxicityOtorhinolaryngologychemistryBiological AssaybusinessTrioxideArchives of Oral Biology
researchProduct

An inherited deficiency of the third component of complement, C3, in guinea pigs

1986

Hereditary deficiency of the third component of complement, C3, is found very seldom in the human. C3 deficiency is associated with severe bacterial infections revealing the central role of C3 in complement activation via the classical or alternative pathway. We describe a new hereditary C3 deficiency in strain 2 guinea pigs. Serum from these animals had a markedly reduced lytic activity in a standard assay for complement-dependent, antibody-mediated cytotoxicity. In functional assays of individual components, the hemolytic activity of the components C4, C2, C5 and of factors B, D and H was in the normal range. The functional C3 titer, and similarly C3 antigenic activity in the serum of the…

Blood Bactericidal ActivityGuinea PigsImmunologyMacrophage-1 Antigenchemical and pharmacologic phenomenaBiologyHemolysisMajor Histocompatibility ComplexGuinea pigInbred strainAntigenIn vivoAnimalsImmunology and AllergyComplement ActivationRecombination GeneticComplement C3Molecular biologyIn vitroPedigreeReceptors ComplementComplement systemImmunologyAlternative complement pathwaybiology.proteinC3a receptorEuropean Journal of Immunology
researchProduct

Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular …

2012

Abstract Background and aims Metformin is the first-line therapy in type 2 diabetes. In patients inadequately controlled with metformin, the addition of a sulfonylurea or pioglitazone are equally plausible options to improve glycemic control. However, these drugs have profound differences in their mechanism of action, side effects, and impact on cardiovascular risk factors. A formal comparison of these two therapies in terms of cardiovascular morbidity and mortality is lacking. The TOSCA.IT study was designed to explore the effects of adding pioglitazone or a sulfonylurea on cardiovascular events in type 2 diabetic patients inadequately controlled with metformin. Methods Multicentre, random…

Blood GlucoseMaleBIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICAEndocrinology Diabetes and Metabolismpioglitazone sulfonylurea type 2 diabetes metformin cardiovascular eventsMedicine (miscellaneous)Type 2 diabetesSettore MED/13 - EndocrinologiaBody Mass Indexlaw.inventionRandomized controlled trialRisk FactorslawSurveys and QuestionnairesCardiovascular DiseasepioglitazonepiogllitazoneStrokeDiabetes Therapy PioglitazoneNutrition and DieteticsDiabetesThiazolidinedionecardiovascular events; pioglitazone; Type 2 Diabetes Mellitus; sulphonylureasType 2 diabetesMiddle AgedMetforminSulfonylurea CompoundTreatment OutcomeTolerabilitysulphonylureasCardiovascular DiseasesDrug Therapy CombinationFemaletype 2 diabetesCardiology and Cardiovascular MedicineHumanmedicine.drugmedicine.medical_specialtyEndpoint Determinationsulfonylureacardiovascualr eventSudden deathFollow-Up Studiecardiovascular eventsInternal medicineDiabetes mellitusmedicineHumansHypoglycemic Agentssulfonylureasinterventio trialtype 2 diabetes; cardiovascular events; pioglitazone; sulfonylureas; randomized controlled trialAgedHypoglycemic AgentQuestionnairebusiness.industryRisk Factormedicine.diseaseSurgeryType 2 Diabetes MellitusSulfonylurea CompoundsDiabetes Mellitus Type 2randomized controlled trialQuality of LifeThiazolidinedionesTherapybusinessmetforminPioglitazoneFollow-Up Studies
researchProduct

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1…

2012

OBJECTIVE We evaluated the addition of liraglutide to metformin in type 2 diabetes followed by intensification with basal insulin (detemir) if glycated hemoglobin (A1C) ≥7%. RESEARCH DESIGN AND METHODS In 988 participants from North America and Europe uncontrolled on metformin ± sulfonylurea, sulfonylurea was discontinued and liraglutide 1.8 mg/day added for 12 weeks (run-in). Subsequently, those with A1C ≥7% were randomized 1:1 to 26 weeks’ open-label addition of insulin detemir to metformin + liraglutide (n = 162) or continuation without insulin detemir (n = 161). Patients achieving A1C <7% continued unchanged treatment (observational arm). The primary end point was A1C change bet…

Blood GlucoseMaleEXENATIDEendocrine system diseasesdiabetes liraglutide metfortmin hypoglycemiaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentType 2 diabetesTHERAPYGastroenterologyMELLITUSInsulin DetemirGlucagon-Like Peptide 1GLYCEMIC CONTROLOriginal ResearchInsulin detemirAged 80 and overClinical Care/Education/Nutrition/Psychosocial ResearchTREATED PATIENTSMiddle AgedMetforminMetforminNPH INSULINInsulin Long-ActingFemaleLife Sciences & Biomedicinehormones hormone substitutes and hormone antagonistsmedicine.drugAdultmedicine.medical_specialtyPARALLEL-GROUPAdolescentmedicine.drug_classHypoglycemiaEndocrinology & MetabolismDiabetes mellitusInternal medicineInternal MedicinemedicineHumansHypoglycemic AgentsCOMBINATIONAgedGlycated HemoglobinAdvanced and Specialized NursingScience & TechnologyLiraglutidebusiness.industryInsulin26-WEEKnutritional and metabolic diseasesLiraglutideEFFICACYmedicine.diseaseSulfonylureaEndocrinologyDiabetes Mellitus Type 2business
researchProduct

Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospe…

2019

Abstract Aims According to cardiovascular outcome trials, some sodium‐glucose contransporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are recommended for secondary cardiovascular prevention in type 2 diabetes (T2D). In this real‐world study, we compared the simultaneous reductions in HbA1c, body weight and systolic blood pressure after initiation of dapagliflozin or GLP‐1RA as second or a more advanced line of therapy. Materials and methods DARWIN‐T2D was a retrospective multi‐centre study conducted at diabetes specialist clinics in Italy that compared T2D patients who initiated dapagliflozin or GLP‐1RA (exenatide once weekly or liraglutide). Data were c…

Blood GlucoseMaleGlycated Hemoglobin AEndocrinology Diabetes and MetabolismBlood PressureType 2 diabetes030204 cardiovascular system & hematologySettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesClinical endpointMedicineDapagliflozinGLP-1 analogueMiddle AgedTreatment Outcomeglycaemic controlantidiabetic drug; dapagliflozin; GLP-1 analogue; glycaemic control; observational studyCombinationOriginal ArticleDrug Therapy CombinationFemaleType 2medicine.drugAdultmedicine.medical_specialty030209 endocrinology & metabolismGlucagon-Like Peptide-1 Receptor03 medical and health sciencesDrug TherapyGLP-1 analogue; antidiabetic drug; dapagliflozin; glycaemic control; observational studyGLP‐1 analogueInternal medicineDiabetes mellitusInternal MedicineDiabetes MellitusHumansHypoglycemic AgentsBenzhydryl CompoundsAgedRetrospective StudiesGlycated Hemoglobinantidiabetic drugantidiabetic drug; dapagliflozin; GLP-1 analogue; glycaemic control; observational study; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus Type 2; Diabetic Angiopathies; Drug Therapy Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Retrospective Studies; Treatment Outcomebusiness.industryLiraglutideBody WeightRetrospective cohort studyOriginal ArticlesdapagliflozinLiraglutidemedicine.diseaseBlood pressureDiabetes Mellitus Type 2chemistryPropensity score matchingExenatideobservational studybusinessAntidiabetic drug dapagliflozin GLP-1 analogue glycaemic control observational studyDiabetic Angiopathies
researchProduct

Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus.

2021

Background and aims: To evaluate the change in circulating serum irisin and interleukin-6 (IL-6), in patients with type 2 diabetes mellitus (T2DM) after 6 and 12 months of GLP-1 treatment. Methods and results: Eighty-five patients with T2DM inadequately controlled with insulin or other hypoglycaemic drugs were added to dulaglutide (N° = 44) and liraglutide (N° = 41) treatment. After 6 months of GLP-1 analogues a significant decrease in BMI (p < 0.001), waist circumference (WC) (p < 0.001), fasting blood glucose (p < 0.001), HbA1c (p < 0.001), total cholesterol (p < 0.001), LDL-cholesterol (p = 0.003), triglycerides (p = 0.017), IL-6 (p = 0.045) and a significant increase in s…

Blood GlucoseMaleIrisinmedicine.medical_specialtyTime FactorsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentRecombinant Fusion ProteinsGlucagon-Like PeptidesMedicine (miscellaneous)IncretinsGlucagon-Like Peptide-1 ReceptorSettore MED/13 - EndocrinologiaProinflammatory cytokineAdipokineInternal medicineMyokinemedicineHumansHypoglycemic AgentsInsulinIn patientDulaglutideGlucagon-like peptide 1 receptorAgedNutrition and DieteticsLiraglutidebusiness.industryInterleukin-6InsulinType 2 Diabetes MellitusLiraglutideMiddle AgedFibronectinsImmunoglobulin Fc FragmentsSettore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicaEndocrinologyCholesterolTreatment OutcomeDiabetes Mellitus Type 2DulaglutideDrug Therapy CombinationFemaleInflammation MediatorsWaist CircumferenceCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Beneficial Effect of Docosahexanoic Acid and Lutein on Retinal Structural, Metabolic, and Functional Abnormalities in Diabetic Rats

2009

To assess the effect of docosahexanoic acid (DHA) and lutein (both compounds with anti-inflammatory and antioxidant properties) on experimental diabetic retinopathy.Male Wistar rats were studied: non-diabetic controls, untreated diabetic controls, and diabetic rats were treated with DHA and lutein or the combination of DHA + insulin and lutein + insulin for 12 weeks. Oxidative stress and inflammatory markers, apoptosis, and functional tests were studied to confirm biochemical and functional changes in the retina of diabetic rats. Malondialdehyde (MDA), glutathione concentrations (GSH), and glutathione peroxidase activity (GPx) were measured as oxidative stress markers. TUNEL assay and caspa…

Blood GlucoseMaleLuteingenetic structuresmedicine.medical_treatmentApoptosismedicine.disease_causeAntioxidantschemistry.chemical_compoundMalondialdehydeInsulinFluorescent Antibody Technique Indirectchemistry.chemical_classificationCaspase 3NitrotyrosineGlutathione peroxidaseAnti-Inflammatory Agents Non-Steroidalfood and beveragesMalondialdehydeGlutathioneSensory SystemsDrug Therapy Combinationmedicine.medical_specialtyDocosahexaenoic AcidsEnzyme-Linked Immunosorbent AssayBiologyRetinaDiabetes Mellitus ExperimentalCellular and Molecular NeuroscienceDiabetes mellitusInternal medicineElectroretinographyIn Situ Nick-End LabelingmedicineAnimalsRats WistarGlutathione PeroxidaseDiabetic RetinopathyInsulinLuteinGlutathionemedicine.diseaseeye diseasesRatsOxidative StressOphthalmologyEndocrinologychemistryTyrosinesense organsBiomarkersOxidative stressCurrent Eye Research
researchProduct

The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with …

2012

Aims The objective was to assess the consistency of effect of switching to ezetimibe/simvastatin 10/20 mg versus doubling the baseline statin dose (to simvastatin 40 mg or atorvastatin 20 mg) or switching to rosuvastatin 10 mg across subgroups of subjects with (n = 617) and without (n = 191) metabolic syndrome (MetS). Methods This was a post hoc analysis of a randomized, double-blind, 6-week study of adults 18–79 years with cardiovascular disease and diabetes mellitus with low-density lipoprotein cholesterol (LDL-C) ≥70 and ≤160 mg/dl. The percent change in LDL-C and other lipids was estimated within each subgroup separately. Safety and tolerability were assessed. Results In subjects with M…

Blood GlucoseMaleSimvastatinEndocrinology Diabetes and MetabolismAtorvastatinEzetimibe Simvastatin Drug CombinationPharmacologyEndocrinologyAtorvastatinMedicineRosuvastatin CalciumMetabolic SyndromeSulfonamidesAnticholesteremic AgentsFastingMiddle AgedDrug CombinationsTreatment OutcomeTolerabilityCardiovascular Diseaseslipids (amino acids peptides and proteins)Drug Therapy CombinationFemalemedicine.drugAdultmedicine.medical_specialtyStatinAdolescentmedicine.drug_classUrologyDrug Administration ScheduleEzetimibeDouble-Blind MethodDiabetes mellitusInternal MedicineHumansRosuvastatinPyrrolescardiovascular diseasesAgedApolipoproteins Bbusiness.industrynutritional and metabolic diseasesCholesterol LDLmedicine.diseaseFluorobenzenesDiabetes Mellitus Type 1PyrimidinesDiabetes Mellitus Type 2SimvastatinHeptanoic AcidsAzetidinesMetabolic syndromebusinessDiabetic AngiopathiesDiabetes, obesitymetabolism
researchProduct